Physician profile
Daniel L Johnson
NPI 1124199690
$1,879.42
in general payments reported to CMS, 2019-2025
27 companies · $562 in 2025
The $562 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $250 · 2022: $656 · 2023: $395 · 2024: $16.16 · 2025: $562.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $972.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $223.12 | 2021-2025 | Ozempic, Wegovy |
| Amgen INC. | $180.86 | 2021-2025 | Otezla, Repatha, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $162.11 | 2022-2025 | Caplyta |
| Lilly USA, LLC | $160.47 | 2021-2025 | Mounjaro, Trulicity, Jardiance |
| Merck Sharp & Dohme LLC | $154.64 | 2021-2025 | Verquvo, Vaxneuvance, Enflonsia |
| Abbott Laboratories | $151.24 | 2021-2025 | Freestyle Libre |
| Astrazeneca Pharmaceuticals LP | $135.90 | 2021-2025 | Evusheld, Airsupra, Farxiga |
| Novartis Pharmaceuticals Corporation | $97.25 | 2022-2023 | |
| Abbvie INC. | $93.04 | 2021-2025 | |
| Pfizer INC. | $61.39 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.13 | 2022-2024 | |
| Dexcom, INC. | $54.61 | 2023-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.23 | 2022-2023 | Spiriva Respimat |
| Glaxosmithkline, LLC. | $44.85 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $34.65 | 2025 | Daybue |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $28.27 | 2022-2023 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $24.94 | 2022 | |
| Radius Health, INC. | $24.24 | 2025 | Tymlos |
| Exact Sciences Corporation | $18.65 | 2025 | The Cologuard Plus Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $17.87 | 2022 | |
| Xeris Pharmaceuticals, INC. | $16.95 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.21 | 2025 | Xifaxan |
| Edwards Lifesciences Corporation | $14.70 | 2022 | |
| Eisai INC. | $13.92 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.84 | 2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $12.47 | 2022 | |
| Sanofi-Aventis U.S. LLC | $11.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.